A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

NCT06972459 · Active, not recruiting

Last updated 2026-05-28

This study is testing the investigational medication Orforglipron (LY3502970) in adults with obesity or overweight who also have at least one weight-related health condition to see how it affects their body weight over time.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 600 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-05 · est. completion 2027-08

Where 80 sites · Argentina, China, Czechia, Germany, Japan, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT06972459 ↗

Description as written by the study sponsor.

The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06972459 ↗